GREENVILLE, S.C., June 26 /CNW/ -- Signalife, Inc. (Amex: SGN - News)
announced today that it has received Industry Canada (IC) certification which
allows the importation of the Signalife Fidelity 100 ECG Monitor System for
marketing and sale into Canada. The certification states that the device is
in compliance with the necessary requirements for medical devices of this
type. Therefore, the Fidelity 100 may be marketed in, and legally imported
from the United States into Canada.
Revenues for ECG devices in the Canadian market exceeded $200 million in
2006. Canada's health care system is a group of socialized health insurance
plans that provides coverage to all Canadian citizens. It is publicly funded
and administered on a provincial or territorial basis, within guidelines set
by the federal government.
Under the Canadian health care system, individual citizens are provided
preventative care and medical treatments from primary care physicians as well
as access to hospitals, dental surgery and additional medical services. With a
few exceptions, all citizens qualify for health coverage regardless of medical
history, personal income, or standard of living.
Canada does boast one of the highest life expectancies (about 80 years)
and lowest infant morality rates of industrialized countries, which many
attribute to Canada's health care system.
"Approval to sell our product in Canada is another significant milestone
for the company as the country's focus on preventative healthcare will be
addressed by the signal quality of the Fidelity 100 and its ability to detect
minimal cardiac problems at an early stage of the disease progression, thus
arming physicians with better diagnostic data. The access to more accurate
data may allow physicians to utilize various treatment options for patients
before cardiovascular disease progresses to its most debilitating stages,"
states Pam Bunes, CEO of Signalife, Inc.
Signalife, Inc. is a life sciences company focused on the monitoring and
detection of disease through continuous biomedical signal monitoring.
Signalife uses its patented signal technology to design and develop medical
devices that simplify and reduce the costs of diagnostic testing and patient
monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the
symbol SGN. The website for the company is http://www.Signalife.com. Clear
Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-
looking" statements. Forward-looking statements involve known and unknown
risks, which may cause Signalife's actual results in the future to differ
materially from expected results. Factors which could cause or contribute to
such differences include, but are not limited to, failure to complete the
development and introduction of heart monitoring and other biomedical devices
incorporating Signalife's technology, failure to obtain federal or state
regulatory approvals governing heart monitoring and other biomedical devices
incorporating Signalife's technology, inability to obtain physician, patient
or insurance acceptance for heart monitoring and other biomedical devices
incorporating Signalife's technology, and the unavailability of financing to
complete management's plans and objectives, including the development of heart
monitoring and other biomedical devices incorporating Signalife's technology.
These risks are qualified in their entirety by cautionary language and risk
factors set forth and to be further described in Signalife's filings with the
Securities and Exchange Commission.
For further information:
For further information: Kevin Kading of Signalife, Inc.,
+1-212-918-4606 Web Site: http://www.signalife.com